Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) shares traded down 6.7% during trading on Monday . The stock traded as low as $8.28 and last traded at $8.50. 187,663 shares changed hands during mid-day trading, an increase of 186% from the average session volume of 65,524 shares. The stock had previously closed at $9.11.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the company. Guggenheim reduced their price target on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $17.00 price target on shares of Valneva in a research report on Tuesday, April 15th.
View Our Latest Analysis on VALN
Valneva Price Performance
The firm has a market cap of $799.85 million, a PE ratio of -7.90 and a beta of 1.77. The company has a quick ratio of 2.12, a current ratio of 2.70 and a debt-to-equity ratio of 0.92. The stock has a 50 day moving average price of $6.57 and a two-hundred day moving average price of $6.64.
Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. Valneva had a negative return on equity of 43.05% and a negative net margin of 43.08%. As a group, equities analysts expect that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current year.
Institutional Investors Weigh In On Valneva
An institutional investor recently bought a new position in Valneva stock. GAMMA Investing LLC acquired a new stake in Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,964 shares of the company's stock, valued at approximately $94,000. 11.39% of the stock is currently owned by institutional investors.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Further Reading
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access